EP2701741
DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO PATIENTS AT RISK FOR POTENTIAL ADVERSE EFFECTS
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
30.4.2012EP published:
10.6.2020EP application number:
12724289.9
EPO information:
European Patent Register
Max expiry date:
29.4.2032
Title:
DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO PATIENTS AT RISK FOR POTENTIAL ADVERSE EFFECTS
Timeline
Today
30.4.2012EP application
10.6.2020EP Publication
Owner
Name:
Amgen Research (Munich) GmbHAddress:
Staffelseestrasse 2, 81477 München, DE
Inventor
Name:
NAGORSEN, DirkAddress:
81477 München, DE
Priority
Number:
201161479961 PDate:
28.4.2011Country:
US
Classification
Categories:
A61K 39/395, A61P 35/02, C07K 16/28